Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the AAD 2023 Innovation Academy Meeting
THU, AUG 03, 2023 15:02 CETReport this content
Oslo, 3 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that an abstract from its licensing partner Verrica Pharmaceuticals Inc (“Verrica”) is accepted for presentation at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy.

Verrica’s presentation is titled “VP-315, an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma” and will highlight the antitumor activity of LTX-315 - by Verrica designated as VP-315 - as determined by clinical and histological clearance of treated BCC lesions from the Verrica’s ongoing Phase II trial. The data will be presented at the 2023 American Academy of Dermatology 2023 Innovation Academy meeting, which is being held from August 10-13, 2023, in Tampa, Florida.

Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize LTX-315 for dermatologic oncology indications and is currently performing a clinical Phase II study in patients with basal cell carcinoma (BCC). In April 2023 Verrica announced that the first patient was dosed in Part 2 of the study. The progress into Part 2 was based on positive results from the completed Part 1 of the study, where LTX-315 showed clinical evidence of activity in patients who received a higher dose range.

Basal cell carcinoma is the most common form of cancer in the U.S., and incidence is rising worldwide. There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options. Basal cell carcinoma is generally treated with invasive surgery to remove the tumor, which can cause pain, infection, bleeding and scarring. LTX-315 could play a significant role as part of an alternative therapeutic regimen to surgery.

Under the terms of the license agreement, Lytix was entitled to receive an upfront payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of up to USD 111 million in total. In addition, Lytix is entitled to receive tiered royalties based on worldwide annual sales.

The focus of the 2023 AAD Innovation Academy meeting is innovations that can change how dermatology is being practiced. For more information about the conference, follow link: https://www.aad.org/member/meetings-education/ia23

To view the full announcement from Verrica, please visit https://verrica.com/press_release/verrica-pharmaceuticals-announces-acceptance-of-abstract-featuring-clinical-data-of-vp-315-for-the-treatment-of-basal-cell-carcinoma-at-the-american-academy-of-dermatology-associations-aad/

For more information, please contact:
Ole Peter Nordby, Head of IR & Communication Manager: ole.peter.nordby@lytixbiopharma.com

Lytix in brief:

Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 target cancer cells and disintegrate their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.

Subscribe

©CisionPrivacy

Tok et lodd, enten eller i Biotech. Takker for tipset. Opp 10% nå

7800kr så er denne på 12,4kr

Jeg tipper vi ser en dobling i dag?

ja, gleder meg til resten av uken.

Opp 29%, reprising på gang. Dette blir nye raketten?

Kommer det god presentasjon ny utvikling av vaksine, så dobles Lytix

Med kurs 8,85 er Lytix priset til ca. 355 mill.
Hvis de lykkes er det ikke snakk om dobling av kursen, men heller en 50 dobling.
Selskapet vil kunne bli et selskap på nivå med Algeta ved oppkjøp, de ble solgt for 15,7 mrd. om jeg ikke husker helt feil.
Lytix vil få milepælsutbetalinger på i overkant av 1,0 mrd. fra Verrica og deretter en andel av salgsinntektene (vet ikke fordelingen mellom selskapene).
Dette er bare for LTX-315 og selskapet har flere kandidater i pipeline.

Aksjen vil etter alle solemerker begynne vandringen nedover fra i morgen. Det blir solgt 3 til 5 aksjer til 70-80 øre under siste omsatte, og slik går nå dagan til den er nede i 6-7 kr.

Spennende nå for Lytix. Presentasjon i USA fra torsdag av. Holdes litt tilbake i påvente av resultatene preclinical studies

Dette blir interessant og spennende for aksje kursen.

Kan fort se 20+

En Biotech aksje som kan overraske. Ingen grenser hva Lytix kan stige til hvis de lykkes

rally

Valuation: Sum of LTX-315, Verrica deal and LTX-401
We value LTX-315 in the main indication of metastatic melanoma and in three sub-indications.
We include a licensing agreement worth USD500m (USD40m upfront and 13.5% in royalties).
For LTX-401, we include a licensing agreement worth USD300m (USD9m upfront and 12% in
royalties). We value the deal with Verrica separately. Assuming some dilution due to NOK80m
being raised in 2024, our base case is NOK14.

Fått kursmål på 14 kr

Kan være greit å legge denne ut på ny, siden den forklarer på en god måte virkemåte og potensialet til Lytix sine kreftmedisiner.

https://www.healthtalk.no/ltx-315-lytix-biopharma-onkolytisk-virus/lytix-biopharma-sjefen-ser-lyse-tider-for-selskapets-utprovende-kreftmedisiner/169567

Tar med denne også.
Når en Nobelprisvinner har ståltro på hva Lytix driver med, så kanskje vi skal stole på han?
https://www.tv2.no/nyheter/utenriks/hundretusenvis-av-liv-kan-bli-reddet/15718730/

hva skjer noen som vet noe?

i kveld åpnes champagnen.

Åpner snart opp.

Vi må gi Lytix litt pusterom, har akkurat begynt sakte stigning. Må se til høsten, kanskje vi er på 12 kr

Håper vi får nyhetene i dag (helst før OSE stenger) men uansett best å være inne før børs åpningen i morra.

Denne kan gå bra med gode nyheter og nå kursmål på 14 kr

"Ved injeksjon av LTX 315 kollapser kreftceller i løpet av 20 minutter".

Det er dette de prøver å lage vaksine på, et nytt medisinsk gjennombrudd. IPO var på 18 kr. Håper på det beste fremover

Rally?

To view the full announcement from Verrica, please visit

https://verrica.com/press_release/verrica-pharmaceuticals-announces-acceptance-of-abstract-featuring-clinical-data-of-vp-315-for-the-treatment-of-basal-cell-carcinoma-at-the-american-academy-of-dermatology-associations-aad/

Gratulere:) skal opp i morgen.

Da kom meldingen vi ventet på!
Dette bør tilsi en kraftig oppgang i Lytix i dag (og fremover).
Ny melding fra: Lytix Biopharma AS: Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315

Promising clinical results showed clearance of basal cell carcinoma lesions in 4 of 6 patients.
• Potential as non-surgical therapeutic approach for basal cell carcinoma, the most common form of cancer in the US

Oslo, 11 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage biotech using host-defense peptide derived molecules to kill cancer cells and kick start the immune system, announces that its licensing partner Verrica Pharmaceuticals Inc (“Verrica”) has reported lesion clearance data from Part 1 of an ongoing Phase II study of VP-315 (formerly known as LTX-315) for the treatment of basal cell carcinoma (BCC). Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize LTX-315 for dermatologic oncology indications and is currently performing a clinical Phase II study in patients with BCC.

The results were orally presented at the 2023 American Academy of Dermatology Innovation Academy meeting, August 10-13, in Tampa, Florida. The presentation titled “VP-315, an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma” highlights the antitumor activity of LTX-315 - designated as VP-315 by Verrica - as determined by clinical and histological clearance of treated BCC lesions from Part 1 of its ongoing Phase II trial (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05188729&data=05%7C01%7Cgunnar.oye%40nho.no%7Cfd5d2eda6b7f47c07e6408db9a311371%7C21be13a8b92f4a809cf317026d4a8118%7C0%7C0%7C638273307792258714%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=yB5mRkyofg0Jw3I3sSNU91bF5cA9wjEij2DE4xdIbsk%3D&reserved=0).

In the presentation, Dr. Neal Bhatia MD, Director of Clinical Dermatology Therapeutics Clinical Research in San Diego, stated:
* Subjects received once daily dosing of VP-315, administered intratumorally, in up to two biopsy-proven BCC lesions for up to six treatments over a two-week period.
* Six lesions were treated at the 8 mg dose and post-treatment clinical assessment and excisions were performed at Day 49 (Range 35-70), followed by histological evaluation.
* Consistent clinical and histological clearance of treated BCC lesions was observed by Day 49 post-treatment with the 8 mg dose of VP-315, with 4 of 6 subjects (67%) showing complete tumor clearance. The other 2 subjects showed a partial response in tumor burden reduction (95% tumor clearance and 30% tumor clearance).
* Optimization of the 8 mg dosing regimen is under investigation in Part 2 of the study.
* These early encouraging results from Part 1 support VP-315 as a potential non-surgical therapeutic approach for BCC.

Øystein Rekdal, CEO of Lytix, commented on the results: “It is very encouraging to see that a majority of patients receiving the higher range of VP-315 dosing experienced complete tumor clearance. We now look forward to seeing the results from Part 2 of Verrica`s Phase II study investigating the optimization of the dosing regime, which Verrica expect to be concluded in the first half of 2024.”

In April 2023, Verrica announced that the first patient was dosed in Part 2 of the study. The progress into Part 2 was based on positive results from the completed Part 1 of the study, where LTX-315 already has showed positive clinical and histologic results.
Basal cell carcinoma is the most common form of cancer in the U.S., and incidence is rising worldwide. There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options. Basal cell carcinoma is generally treated with invasive surgery to remove the tumor, which can cause pain, infection, bleeding and scarring. LTX-315 could play a significant role as part of an alternative therapeutic regimen to surgery.

Under the terms of the license agreement, Lytix was entitled to receive an upfront payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of up to USD 111 million in total. In addition, Lytix is entitled to receive tiered royalties based on worldwide annual sales.

The focus of the 2023 AAD Innovation Academy meeting is innovations that can change how dermatology is being practiced. For more information about the conference, follow link: https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.aad.org%2Fmember%2Fmeetings-education%2Fia23&data=05%7C01%7Cgunnar.oye%40nho.no%7Cfd5d2eda6b7f47c07e6408db9a311371%7C21be13a8b92f4a809cf317026d4a8118%7C0%7C0%7C638273307792258714%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=QtrCenyvYVS9RwcO1%2F9%2Fu1fGvgEg7IUDBY7%2BN5ZJFhQ%3D&reserved=0

11.08.2023 08:31:56
LYTIX: LISENSPARTNER RAPPORTERER LOVENDE RESULTATER I LTX-315-STUDIE
Oslo (Infront TDN Direkt): Lytix Biopharmas lisenspartner Verrica Pharmaceuticals har rapportert midlertidige data fra fase II i LTX-315-studien som viser lovende kliniske resultater for fjerning av basalcellekarsinom-lesjoner (BCC) hos fire av seks pasienter.

Spennende å se hvor mye vi skal opp på denne børs meldingen

Dette kan ta helt av. Sitter i rett Biotech aksje nå

Positiv omtale av Lytix i dagens Finansavis.
https://www.finansavisen.no/helse/2023/08/11/8028243/revolusjonerende-kreftstudie-sender-aksje-til-vaers?internal_source=sistenytt

Kan gå over 20% idag, 10 kr

"De gode resultatene medfører at vaksinen kan være den første ikke-kirurgiske måten å fjerne hudkreft på, som er den mest vanlige formen for kreft i USA. Resultatene er så gode at de kan fremskynde det kliniske utviklingsarbeidet"

Kursmål på 26 kr godt scenario er mer realistisk nå

Vanvittig bra🫶 vil tro selskapet blir kjøpt opp

Bør vel komme mer i media om denne sensasjonen. Bra for selskapet og ikke minst godt nytt for kampen med å bekjempe kreft

Ikke minst de kan gjør hverdagen enklere for alle pasientene, mindre ventetid, kan redde mange liv. Håper de fortsetter med å vise gode resultater

Hadde dette vært på Stockholm børsen så hadde aksjen gått mange mange 10-talls prosent.

https://www.finansavisen.no/helse/2023/08/11/8028243/revolusjonerende-kreftstudie-sender-aksje-til-vaers

Får prøve en inngang her, men avventer hvor langt ned gevingstgutta er villig til å gå